← Tra cứu cổ phiếu

iShareInvest Research

HNX · Quý 2/2026

MED

Dược Trung ương Mediplantex

Analysis of business results & financial statements · Quý 2/2026

▲ Showing improvement

Trailing net profit reached 21.3bn, rose 7.5bn compared with the same period last year. Key positives came from lower administrative expenses and lower selling expenses. Offsetting pressure came mainly from lower gross profit, higher tax, and lower financial income. Detailed impact is shown below:

See what is changing ↓
P/E
10.74x
P/B
0.67x
EPS
1,714
BVPS
27,414
ROE
6.4%
ROA
4.5%
Market price
18,400
15 Jul 2026

What Is Changing

On a TTM 2026Q2 basis, MED has not accelerated revenue, but profitability is improving more visibly — profit is at an all-time high. The positive sign is better operations, though this signal only becomes convincing if accompanied by a revenue recovery.

Profit bridge

Vs last year · TTM

  1. Administrative expenses
  2. Selling expenses
  3. Gross profit
  4. Tax
  5. Financial income
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 2/2026

MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24
Revenue122.988.7117.687.1162.375.4105.992.2
LNST5.35.96.13.95.22.22.93.5
Net margin4.30%6.68%5.22%4.49%3.22%2.89%2.74%3.78%

Revenue

123bn

Net income

5bn

Net margin

4.30%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins are improving and earnings quality is solid — a durable foundation for ROE.

Revenue Growth

●

Is growth real and durable?

Trailing-12-month revenue declined 4.5% year on year — but the quarterly pace is slowing (−6% → −24%).

2 of the last 4 quarters grew year on year.

Revenue TTM
416bn
−4.5%
Latest quarter YoY
−24%
slowing

What is driving the margin?

▲

Net margin expanded to 5.11%, rising 1.9pp. Core operating signals are improving as SG&A / Revenue fell 4.2pp are enough to offset pressure from Gross margin fell 1.7pp (with lingering pressure from Net financial result / Revenue fell 0.2pp).

The improvement comes from core operations — this is a high-quality margin expansion.

Net Margin
5.11%
+1.9pp
Gross Margin
21.65%
−1.7pp
SG&A / Revenue
14.56%
−4.2pp

TTM YoY · 2025Q2 -> 2026Q2

Cash Flow

●

Is profit converting into cash?

Operating cash flow reached -5.4bn against investing cash flow of -4.0bn (annual cash-flow figures for 2025).

Post-investment cash flow was negative +9.3bn. Financing cash flow was negative +8.9bn.

CFO / net income was 0,44 lần.

Track how much investment can be funded internally from operating cash flow.

Cash capex or FCF data is incomplete, so the cash-conversion view is only partial.

Earnings Quality

▲

How much income is non-core?

About 100% of pre-tax profit comes from core operations.

Within that, net financial result at −11.5% of PBT.

Non-core / PBT
0.0%
low
Net financial / PBT
−11.5%
02

Is capital being used efficiently?

Capital is being used more efficiently — ROIC rose and cash cycle shortened to 98.1 days.

Is capital being deployed efficiently?

▲

ROIC expanded to 5.77%, rising 2.0pp. That translates to 5.77 in after-tax operating profit for every 100 units of operating capital. The main driver is NOPAT margin rose 1.7pp, with capital turnover broadly stable; with invested capital holding roughly steady.

NOPAT margin led the improvement, but the ROIC level has not yet cleared typical cost of capital — margin needs to hold in coming periods rather than being a one-period rebound.

Working Capital Efficiency

▲

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 16.3 days versus the same period last year. The main moves came from DIO fell 0.6 days, DSO fell 25.8 days, and DPO fell 10.0 days.

Improvement comes mainly from faster receivables collection — reflects the quality of receivables management.

Cash conversion cycle remains stretched

CCC stands at 98.1 days, suggesting that working capital remains tied up for a relatively long operating cycle.

DuPont

What drives ROE?

Net margin 5.1% +1.9pp
Asset turnover 0.88x +0.09x
Financial leverage 1.43x -0.26x
ROE 6.4% +2.2pp

ROE rose from 4.2% to 6.4% — mainly driven by net margin, despite leverage moving in the opposite direction.

03

Is financial risk significant?

Check leverage, liquidity, and cash-flow conversion.

Leverage & Liquidity

▲

Leverage looks fairly comfortable, with net debt / equity at 0.08x and interest coverage at 6.35x.

At present, short-term debt accounts for 100.0% of total debt, cash equals 40.5% of debt, and total debt stands at 48.4bn.

Net Debt / Equity
0.08x
+0.03x
Interest Coverage
6.35x
+2.62x
Cash / Debt
40.5%
−20.9pp
Short-term Debt / Total Debt
100.0%
0.0pp

TTM YoY · 2025Q2 -> 2026Q2

Short-term refinancing pressure is meaningful

Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.

Balance Sheet

●

The asset structure shows capital being allocated increasingly efficiently. Capital structure is conservative with low leverage — liabilities at 0.38x equity, net debt at 0.08x equity.

Inventory ended the period at 93.2bn, roughly 20.4% of total assets.

Over the last 12 months, working capital absorbed 2.6bn of cash, mainly because of lower payables. Part of that drag was offset by lower receivables and lower inventories.

Research synthesis

What this reporting period is showing

The business is entering a broader improvement phase — not just stronger earnings but better operating quality as well. Margin and capital efficiency all improving shows the business is growing in a cleaner and more efficient way than before. Notably, the improvement trend has been confirmed across multiple cycles, from margin to capital efficiency. Even so, cash generation still needs confirmation remains the area to verify in upcoming periods.

  • Improvement: operating efficiency is getting better, with trailing-12M net margin at 5.11% after expanding 1.9pp versus the same period last year.
  • Watchpoint: Cash generation still needs confirmation.

Questions for the next period

  1. Whether revenue stabilizes after a −4,5% YoY decline or keeps falling.

  2. Whether margins hold around the current 5.11% level or narrow again.

  3. Whether operating cash flow holds its -5.4bn (cumulative for 2025) level in upcoming periods or weakens.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio